Bulletin "Veterinary biotechnology"

Veterynarna biotehnologija – Veterinary biotechnology, 2018, 32(1), 56-60 [in Ukrainian]. https://doi.org/10.31073/vet_biotech32(1)-05

BUZUN A.I., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., STEGNIY B.T., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., KOLCHYK O.V.e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., KOROVIN I.V.


Introduction. In a newly established approach to blind spreading of ASF in Ukraine as concurrent infections (A. Buzun, 2016; A. Buzun, O. Kolchik, 2017), we decided to adapt of our early developed vaccine “ReproSuiVac-IECVM” to prevention of PCV-2, PRRS and Mannheimia haemolytica infections in limited areas around ASF outbreaks.

Aims. Development of vaccine for prevention of the concurrent infections that promote to blind spreading ASF in Ukraine.

Materials and methods. For improvement of vaccine “ReproSuiVac-IECVM” the antitoxin and bacterin of the Mannheimia haemolytica were added to former composition in relations that not cause the antigens competition in vaccine (as tested by seroconversion on correspondence antigens). In addition we replaced the Montanide ISA 70 (Fr.) on KE 1001 emulsion (UA). For research of post-vaccine levels of antibodies in both mice and porcine we used our test-kit “ReproSuiScreen-IECVM” for PRRS- and PCV-2 antibodies and agglutination test with correspondence bacterin for Mannheimia haemolytica antibodies.

Research results and discussion. All vaccinated adult mouse (n=12) at contrast to unvaccinated (n=8) were alive after its inoculation with broth culture of Mannheimia haemolytica in dose 0.5 cm3 (105 BC50) during 1 month of trials. Level of vaccinated mouse seroconversion on PRRS, PCV-2 and bacterial antigens was 0; 1/2.30+0.11 and 1/351.00+5.73 (P<0.01), in correspondence. All vaccinated pigs (n=5) after first injection had a levels of seroconversion on PRRS, PCV-2 and bacterial antigens (3 week after vaccination) 1/8.80+2.05; 1/22.50+7.73 and 1/51.00+6.88 (P<0.05), in correspondence. After revaccination (3 week after first injection) pigs had a levels of seroconversion on PRRS, PCV-2 and bacterial antigens (3 week after second injection) 1/17.40+0.78; 1/34.23+0.73 and 1/121.11+2.44 (P<0.05), in correspondence.

Conclusions. Modified vaccine “ReproSuiVac-IECVM” are ready to clinical trials against the concurrent ASF-hemolytic pasteurellosis infections that promote of blind spreading of ASF agent in the quarantine areas of ASF outbreaks (promote of its attribution) in Ukraine.

Keywords: vaccine, hemolytic pasteurellosis, reproductive and respiratory syndrome, circovirus infection, vaccinations.


  1. Yang, N., Li, J., Yang, Q., Qiao, J., Cui, D., Liu, F. et al. (2018). Reduced antigen presentation capability and modified inflammatory/immunosuppressive cytokine expression of induced monocyte-derived dendritic cells from peripheral blood of piglets infected with porcine circovirus type 2. Arch. Virol., 3, 32–35.
  2. Kvansakul, M., Caria, S. & Hinds, M.G. (2018). The Bcl-2 Family in Host-Virus Interactions. Viruses, 6, 9–10.
  3. Leite, F., Sylte, M.J., O'Brien, S., Schultz, R., Peek, S., van Reeth, K. et al. (2002). Effect of experimental infection of cattle with bovine herpesvirus-1 (BHV-1) on the ex vivo interaction of bovine leukocytes with Mannheimia (Pasteurella) haemolytica leukotoxin. Vet. Immunol Immunopathol, 1, 97–110.
  4. Buzun, A. (2016). Threat of hidden spread of the African swine fever as a concurrent infection in Ukraine. CBEP Ukraine Research Forum and Peer. Review Session, 100, 72–75.
  5. Allan, G.M., Phenix, K.V., Todd, D. & McNulty, M.S. (1994). Some biological and physico-chemical properties of porcine circovirus. Zentralb. Veterinarmed., 41, 17–26.
  6. Jusa, E.R., Inaba, Y., Kohno, M., Mashimo, H. & Hirose, O. (1996). Hemagglutination with porcine reproductive and respiratory syndrome virus. J Vet Med Sci., 58, 521–527.
  7. Jaramillo, L., Díaz, F., Hernández, P., Debray, H., Trigo, F., Mendoza, G. et al. (2000). Purification and characterization of an adhesin from Pasteurella haemolytica. Glycobiology, 1, 31‑37.
  8. Ayalew, S., Shrestha, B., Montelongo, M., Wilson, A.E. & Confer, A.W. (2011). Immunogenicity of Mannheimia haemolytica recombinant outer membrane proteins serotype 1-specific antigen, OmpA, OmpP2, and OmpD15. Clin. Vaccine Immunol. 18, 2067–2074.

Download full text in PDF